Bioharvest Sciences Inc.
BHST Nasdaq Pharmaceutical Preparations Financials FY2023–FY2025
What Bioharvest Sciences Inc. does
No business description yet.
- Legal name
- BIOHARVEST SCIENCES INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 40-F · Mar 31, 2026
- Accession · CIK
- 0001376474-26-000257
0001723464
Revenue and margins
Bioharvest Sciences Inc. had $34.5M of revenue in fiscal 2025, up 37.0% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$9.6M in fiscal 2025, −27.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Bioharvest Sciences Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Bioharvest Sciences Inc. can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $5.4M | $2.4M | $23.0M |
| Debt incl. finance leases | $0.0M | $3.9M | $0.1M |
| Debt / equity | — | 2.9x | 0.0x |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Quick ratio | 0.2x | 0.3x | 3.4x |
| Total liabilities | $29.9M | $23.7M | $22.2M |
| Shareholders' equity | −$14.9M | $1.3M | $25.4M |
| Net debt (− = net cash) | −$5.4M | $1.5M | −$22.9M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | — | — |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✓ | ✓ |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | ✓ | ✓ |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 5 | — / 5 |
| Accruals ratio | — | — | — |
| Altman Z'' | — | — | — |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $12.7M | $25.2M | $34.5M |
| Gross profit | $5.6M | $13.9M | $20.5M |
| Operating income | −$10.0M | −$7.0M | −$5.6M |
| Pretax income | −$12.6M | −$12.9M | −$11.1M |
| Income tax | $0.0M | −$0.0M | −$0.1M |
| Net income | −$12.6M | −$12.9M | −$11.1M |
| Cash flow | |||
| Cash from operations | −$8.5M | −$6.7M | −$7.2M |
| Capital expenditure | $1.5M | $2.8M | $2.4M |
| Free cash flow | −$10.0M | −$9.5M | −$9.6M |
| Depreciation and amortization | $0.8M | $1.3M | $1.6M |
| Stock-based compensation | $0.6M | $0.6M | — |
| Balance sheet | |||
| Cash and short-term investments | $5.4M | $2.4M | $23.0M |
| Total debt | $0.0M | $3.9M | $0.1M |
| Current assets | $9.1M | $7.9M | $30.5M |
| Current liabilities | $26.5M | $14.3M | $7.7M |
| Inventory | $2.5M | $3.7M | $4.6M |
| Property and equipment, net | $3.9M | $7.8M | $8.3M |
| Total liabilities | $29.9M | $23.7M | $22.2M |
| Shareholders' equity | −$14.9M | $1.3M | $25.4M |
| Margins | |||
| Gross margin | 44.5% | 55.4% | 59.3% |
| Operating margin | −78.6% | −27.7% | −16.2% |
| EBITDA margin | −72.0% | −22.8% | −11.4% |
| Net margin | −99.1% | −51.3% | −32.3% |
| FCF margin | −78.9% | −37.8% | −27.8% |
| Returns | |||
| Return on capital | — | −194.1% | −171.2% |
| Return on equity | — | — | −83.2% |
| Return on tangible equity | — | −970.9% | −43.8% |
| Growth | |||
| Revenue growth | — | 98.8% | 37.0% |
| Financial health | |||
| Debt / equity | — | 2.9x | 0.0x |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Quick ratio | 0.2x | 0.3x | 3.4x |
| Capital allocation | |||
| Capex / revenue | 11.6% | 11.3% | 6.8% |
| Stock comp / revenue | 4.4% | 2.4% | — |
Source: SEC EDGAR XBRL filings (CIK 0001723464). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.